EGFR and non-small cell lung carcinoma: In conclusion, this exploratory study established a group of plasma lncRNAs for predicting EGFR mutation status, and this model could serve as a new noninvasive biomarker for the diagnosis of EGFR‐mutant patients with NSCLC and an important indicator for predicting the efficacy of EGFR‐TKI therapy.